In support of this notion, it has been shown that alendronate, a drug used to treat osteoporosis in postmenopausal women, can delay adipogenesis and enhance osteogenesis by reducing the expression of PPARγ, the adipogenic transcription factor, in human mesenchymal stem cells [37]. Here, PPARG is linked to osteoporosis.